SynthesisEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Modeling residual cholesteatoma growth rate: a meta-analysis of individual participant data.
Synthesis in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo create a model of residual cholesteatoma growth rate that can be used to estimate optimal timing of follow-up imaging.
methodsFollowing the recommendations of the PRISMA-IPD guideline and after registering our study protocol on PROSPERO (CRD42023465320), a systematic search was completed in September 2023 and updated in July 2024, conducted in PubMed, Web of Science, Embase, and Cochrane Library. Reference lists of the resulting articles were also searched for potential inclusions. Our search yielded 11,274 articles. Studies with patients of any age and sex diagnosed with residual cholesteatoma were included if data on cholesteatoma size at follow-up were available, collected from imaging results or through second-stage surgery. For statistical analysis, a Monte Carlo simulation approach was applied, and a baseline random-intercept mixed-effects model was fitted.
resultsWe included 11 articles reporting individual data from 163 patients. All but one of these articles proved to be high risk of bias. Our simulation models suggest that 95% of cholesteatomas reach or grow past the size of 3 millimetres (threshold for imaging) after 28-35 months and 95% of reach or grow past the size of 5 millimetres (threshold for intraoperative identification) after 47-58 months.
conclusionAnalyzing previously published data suggests that residual cholesteatoma may only be radiologically detectable on non-EPI DWI MRI after 28-35 months postoperatively in 95% of patients, indicating delayed follow-up for average risk patients compared to current clinical practice. However, this simulation model, based on retrospective data, aims to uncover growth patterns rather than posing as a new guideline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.